All mTOR kinase inhibitors, the GSK3 inhibitor SB216763, the proteasome inhibitor MG132, the protein synthesis inhibitor cycloheximide (CHX) and the antibodies against GSK3α/β, phospho-GSK3α/β (Ser21/9), phospho-Akt (Ser473), Akt, rictor and raptor were the same as described previously 22 (link). The GSK3 inhibitor CHIR99021 was purchased from LC laboratories (Woburn, MA). BKM120 was supplied by Novartis Pharmaceuticals Corporation (East Hanover, NJ). API-1 (NSC177233) was obtained from the National Cancer Institute (Bethesda, MD). MK2206 was purchased from Active Biochem (Maplewood, NJ). Perifosine was supplied by Keryx Biopharmaceuticals, Inc (New York, NY). Oil Red O was purchased from Sigma Chemical Co. (St. Louis, MO). SREBP1 (sc-13551), FASN (sc-55580) and α-tubulin (sc-23948) antibodies were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). ACC antibody (#3662) was purchased from Cell Signaling Technology, Inc. (Beverly, MA). Polyclonal Sin1 antibody (A300-910A) was purchased from Bethyl Laboratories, Inc. (Montgomery, TX).